Leveraging sequences missing from the human genome to diagnose cancer
Jan 2025·
·
1 min read
I. georgakopoulos soares
Equal contribution
,O. yizhar barnea
Equal contribution
Ioannis Mouratidis
Equal contribution
,Et al.
Abstract
Cancer detection using liquid biopsies represents a paradigm shift in early diagnosis. This study leverages sequences missing from the human genome (nullomers) to develop a novel approach for cancer detection and diagnosis.
Type
Publication
Communications Medicine, 5(1)
This work demonstrates how sequences that are absent from the human genome can be leveraged as biomarkers for cancer detection, with potential applications in liquid biopsy-based diagnostics.
Authors
Authors
Authors
Ioannis Mouratidis
(he/him)
Senior Research Engineer/Scientist Associate
Machine learning and genomics researcher with 35 publications (10 first or senior author).
Co-founded AI-driven cancer biomarker startup, authored grants securing $4M+ in competitive funding
and currently lead a 5-member team with a focus in developing novel computational methods and testing
the capabilities and safety profiles of biological foundation models.
Authors